close Video

NEW You can now listen to Fox News articles!

Some patients taking GLP-1 drugs for weight loss have been forced to switch to a different medication due to a change in insurance coverage — and they’re not happy about it.

As of July 1, CVS Caremark — one of the biggest pharmacy benefit managers in the U.S. — dropped Zepbound (tirzepatide) from its preferred drug list, replacing it with Wegovy (semaglutide).

Zepbound — along with its counterpart diabetes medication, Mounjaro — is made by Eli Lilly, while Wegovy is produced by Novo Nordisk, which also makes Ozempic.

CVS CAREMARK DROPS COVERAGE OF POPULAR WEIGHT LOSS DRUG

CVS Caremark blamed rising costs for the change. In a June 27 statement on its website, the company noted that "drug manufacturers are solely responsible

See Full Page